LETTER TO THE EDITOR

Impact of treatment delay due to the pandemic of COVID-19 on the efficacy of immunotherapy in head and neck cancer patients

Gaili Chen†, Qiuji Wu†, Huangang Jiang†, Zheng Li, Xinying Hua, Xiaoyan Hu, Haijun Yu, Conghua Xie and Yahua Zhong*

Abstract
Immunotherapy has been a new standard for recurrent/metastatic head and neck cancers (R/M HNC). One of the prominent characteristics of cancer immunotherapy is the induction of immune memory followed by endured treatment response. However, whether and how a treatment delay would impact on the efficacy of immunotherapy has not been well determined. During the outbreak of COVID-19, a number of cancer patients in Wuhan, the epicenter of the pandemic in China, had experienced long-lasting city lockdown and delay of immunotherapies. Here, we retrospectively analyzed 24 HNC patients treated with immune checkpoint inhibitors in our cancer institute prior to the outbreak of COVID-19 who were re-evaluated after the restoration of regular medical care. Of these 24 patients, 10 patients had achieved complete response (CR) or partial response (PR), 12 patients had achieved stable disease (SD), and 2 patients had received just one cycle treatment without efficacy evaluation before treatment delay. The median delay was 3.75 months (range 1.73–8.17 months). Re-evaluation after treatment delay revealed that ten patients (10/10) who achieved CR or PR, two patients (2/2) who received just one cycle treatment without efficacy evaluation and seven patients (7/12) who achieved SD before outbreak of COVID-19 maintained tumor response after treatment delay. Among the rest five patients who had achieved SD, four patients were re-evaluated as progressive disease (PD) due to treatment delay and one patient died after treatment interruption without re-evaluation. Our results from a small cohort of R/M HNC patients showed that treatment delay of three to four months might have mild, if any, impact on the efficacy of immunotherapy for patients with controlled disease.

Keywords: Head and neck cancers, Immune checkpoint inhibitors, Treatment delay, Tumor response

To the editor
Head and neck cancers are the ninth most common malignancy in the world [1]. Most patients present with locally advanced disease with a high risk of recurrence and metastasis [2]. Recent rapid progression in cancer immunotherapies has demonstrated unprecedented benefits of recurrent/metastatic head and neck cancers (R/M HNC) from immune checkpoint inhibitors (ICIs). As a result, ICIs alone in PD-L1 highly expressing settings or in combination with chemotherapies in the overall population has been recommended as new standard for R/M HNC [3–5].

One of the most distinguished characteristics of immunotherapies is the induction of cancer-specific immunity...
and immune memory response, which could yield endured tumor responses observed in numerous clinical trials [3, 6, 7]. However, the interaction between cancer cells and their immune microenvironment is much complex and the mechanisms of cancer immunotherapy have not been fully understood. Treatment delay caused by reversible treatment toxicities, patient economic difficulties and other reasons is frequent, but its impact on

Table 1 Patients information

| Patient ID | Gender | Age (years) | Primary diagnosis | Failure of disease | Treatment lines | Immunotherapy | Combined chemotherapy | Delay (months) |
|------------|--------|-------------|-------------------|-------------------|----------------|----------------|-----------------------|----------------|
| 1          | M      | 77          | Mandible carcinoma | Recurrence       | First line     | Toripalimab    | Nab-paclitaxel → GEM | 3.27           |
| 2          | M      | 73          | Sino-nasal malignant tumors | Metastasis     | First line     | Pembrolizumab  | Nab-paclitaxel         | 3.23           |
| 3          | F      | 63          | Oral cavity cancer | Metastasis      | First line     | Pembrolizumab  | Nab-paclitaxel         | 3.50           |
| 4          | M      | 51          | Hypopharyngeal carcinoma | Recurrence    | First line     | Toripalimab    | Nab-paclitaxel         | 3.23           |
| 5          | M      | 56          | Nasopharyngeal carcinoma | Recurrence    | Second line    | Toripalimab    | S1                    | 8.17           |
| 6          | F      | 44          | Nasopharyngeal carcinoma | Metastasis    | First line     | Camrelizumab   | GEM                   | 3.27           |
| 7          | M      | 26          | Parotid carcinoma | Metastasis      | First line     | Camrelizumab   | Nab-paclitaxel         | 3.23           |
| 8          | M      | 53          | Oral cavity cancer | Recurrence      | First line     | Camrelizumab   | GP → nab-paclitaxel    | 2.97           |
| 9          | M      | 67          | Oral cavity cancer | Recurrence      | First line     | Toripalimab    | GEM                   | 1.73           |
| 10         | F      | 55          | Oral cavity cancer | Recurrence      | First line     | Pembrolizumab  | Nab-paclitaxel         | 4.57           |
| 11         | M      | 50          | Nasopharyngeal carcinoma | Metastasis    | First line     | Camrelizumab   | Nab-paclitaxel → GEM | 5.57           |
| 12         | M      | 65          | Nasopharyngeal carcinoma | Metastasis    | First line     | Camrelizumab   | GEM                   | 4.13           |
| 13         | M      | 46          | Nasopharyngeal carcinoma | Recurrence    | First line     | Camrelizumab   | GP                    | 3.50           |
| 14         | M      | 30          | Oral cavity cancer | Recurrence      | First line     | Camrelizumab   | GP                    | 4.13           |
| 15         | M      | 58          | Oral cavity cancer | Metastasis      | First line     | Camrelizumab   | Nab-paclitaxel         | 3.13           |
| 16         | M      | 69          | Oral cavity cancer | Recurrence      | First line     | Pembrolizumab  | Nab-paclitaxel         | 4.57           |
| 17         | M      | 68          | Oral cavity cancer | Recurrence      | First line     | Camrelizumab   | Nab-paclitaxel         | 4.00           |
| 18         | M      | 67          | Hypopharyngeal carcinoma | Metastasis   | Fourth line    | Toripalimab    | Vinorelbin            | 4.27           |
| 19         | M      | 73          | Nasopharyngeal carcinoma | Recurrence    | First line     | Camrelizumab   | GEM                   | 5.37           |
| 20         | M      | 52          | Oral cavity cancer | Recurrence      | First line     | Camrelizumab   | GP → nab-paclitaxel    | 2.97           |
| 21         | F      | 69          | Oral cavity cancer | Metastasis      | First line     | Toripalimab    | GEM                   | 4.63           |
| 22         | F      | 70          | Oral cavity cancer | Metastasis      | First line     | Camrelizumab   | GEM → nab-paclitaxel   | 4.37           |
| 23         | M      | 58          | Oral cavity cancer | Recurrence      | First line     | Camrelizumab   | Nab-paclitaxel         | 3.13           |
| 24         | M      | 49          | Nasopharyngeal carcinoma | Recurrence    | Fourth line    | Toripalimab    | Nab-paclitaxel         | 6.13           |

M, male; F, female; GEM, gemcitabine; GP, gemcitabine plus cisplatin; S1, gimeracil and oteracil potassium capsules
treatment efficacy has not been well demonstrated. Cancer patients in Wuhan, the epicenter of the COVID-19 in China, provided valuable clues since they had experienced long-lasting city lockdown and a passive delay of treatments. Therefore, we analyzed the impact of treatment delay on HNC patients treated with immunotherapies in our cancer institute prior to the outbreak of COVID-19.

Twenty-four eligible HNC patients were identified (Table 1), including 19 males and 5 females with a median age of 58 years old. In total, 50% (12/24) of patients were diagnosed with oral cancer patients, 29.2% (7/24) with nasopharyngeal carcinoma and the other 20.8% (5/24) with hypopharyngeal carcinoma, sino-nasal malignant tumors, mandible carcinoma and parotid carcinoma. In total, 41.7% (10/24) of patients had metastatic diseases and 58.3% (14/24) had recurrent diseases. Immunotherapy-based therapy was administered as first-line treatment in 87.5% (21/24), second-line in 4.2% (1/24) and fourth line in 8.3% (2/24) of patients. For ICIs, camrelizumab, toripalimab and pembrolizumab were used in 54.2% (13/24), 29.1% (7/24) and 16.7% (4/24) of patients, respectively. Nab-paclitaxel and gemcitabine were main chemotherapy agents used as combination therapy (22/24, 91.7%). The median time of treatment delay was 3.75 months (range 1.73–8.17 months). The last follow-up time was September 30, 2020. Tumor responses of each patient before treatment discontinuation and after treatment re-initiation were made by three oncologists independently according to the Response Evaluation Criteria in Solid Tumors (RECIST1.1) [8].

Of the 24 patients enrolled, ten patients had achieved CR or PR, two patients had received just one cycle treatment without efficacy evaluation, and twelve patients had achieved SD before outbreak of COVID-19. For the ten patients who had achieved CR or PR before treatment interruption, no disease progression was observed upon re-evaluation after treatment delay. Interestingly, disease control was also seen in those two patients who had received just only one cycle treatment without efficacy evaluation and in seven out of twelve patients who had only achieved SD before treatment interruption (Fig. 1). On the other hand, four patients (4/12) with SD were re-evaluated as PD due to treatment delay and the other one patient (1/12) died after treatment interruption without re-evaluation (Fig. 1). Importantly, we noted that most patients experiencing treatment response and maintained clinical benefit (CR and PR) were those who had longer prior treatment exposure (median exposure time: 4.03 months vs 2.33 months). This might imply that treatment interruption in patients who had only received short-term immunotherapy should be discouraged.

Five patients died until the last follow-up. Patient 8 died of an accidental asphyxia even though he had PR disease. After 4.13 months treatment delay, patient 14 was evaluated as SD with enlarged lesion, he gave up immunotherapy and received only chemotherapy, and eventually he died of disease progression. Patient 17 was evaluated as SD after treatment delay, but he refused further treatment and died 8 months after the treatment interruption. Patient 20 died due to treatment interruption, with
enlarged SD status before COVID-19 outbreak. Patient 24 died of mucosal ulcer bleeding as a result of disease progression. In all, no ≥ Grade 3 immune-related toxicity was observed in all 24 patients.

Collectively, these observations suggested that for those who had achieved CR/PR response to immunotherapy and who had a longer prior treatment exposure, a relatively short treatment delay of about three to four months did not lead to significant treatment failure. Yet for those who had only stable diseases, it is important to find alternative treatments during the treatment interruption since they are more likely to experience disease progression. Importantly, re-initiation of immunotherapy in these patients did not reverse disease progression.

As this is a retrospective study and the sample size is relatively small, these conclusions need to be interpreted with caution.

Abbreviations
CR: Complete response; ICIs: Immune checkpoint inhibitors; OS: Overall survival; PD: Progressive disease; PR: Partial response; RECIST: Response Evaluation Criteria in Solid Tumors; R/M HNC: Recurrent/metastatic head and neck cancers; SD: Stable disease.

Acknowledgements
Not applicable.

Authors’ contributions
YH Zhong, GL Chen and QJ Wu conceived and designed the study and critically revised the manuscript; GL Chen and HG Jiang analyzed and interpreted the patient data and were major contributors in writing the manuscript. All authors read and approved the final manuscript.

Funding
The National Natural Science Foundation of China (Grant Nos. 81602164 and 81803061), Scientific Research Project of Hubei Provincial Health and Family Planning Commission (Grant No. WJ2019H060) and Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund (Grant No. znp2019079) supported this study. The sponsor had no role in the design, analysis or writing of this article.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate
The Medical Ethics Committee of Zhongnan Hospital of Wuhan University approved this study (2020089K).

Consent for publication
Verbal consent for publication was obtained from living patients and the relatives of deceased patients.

Competing interests
The authors declare that they have no competing interests.

Received: 18 October 2020 Accepted: 2 December 2020 Published online: 11 December 2020

References
1. Gupta B, Johnson NW, Kumar N. Global epidemiology of head and neck cancers: a continuing challenge. Oncology. 2016;91:13–23.
2. Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008;83:489–501.
3. Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G, Jr, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915–28.
4. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956–65.
5. Ma BYX, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742). J Clin Oncol. 2018;36:1412–8.
6. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;388:1540–50.
7. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–32.
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.